Olympus Corp. · TSE:7733
Olympus — Olympus Corp Ord — Q1 2026 Earnings Presentation
34 slides from Olympus's earnings presentation, Aug 8, 2025
Slide 1: Consolidated Financial Results for the 1st Quarter of Fiscal Year 2026
Consolidated Financial Results for the 1st Quarter of Fiscal Year 2026 Olympus Corporation | Director, Representative Executive Officer, President and Chief Executive Officer, Bob White | Executive Officer and Chief Financial Officer, Tatsuya Izumi | August 8, 2025
Slide 2: Disclaimer
Disclaimer This material contains forward-looking statements that reflect management’s current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, un
Slide 3: Table of contents
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Table of contents 01 Executive Summary 02 Business Topics CEO 03 1Q of Fiscal Year 2026 Consolidated Financial Results 04 Fiscal Year 2026 Consolidated Forecasts CFO 05 Appendix Page 3 No data copy / No data tra
Slide 4: Executive Summary
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 01 Executive Summary
Slide 5: Executive Summary
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix K F ey Message Executive Summary 1Q of Fiscal Year 2026 Consolidated Financial Results Revenue Adjusted operating profit ¥ 206.5 billion GIS -8 % / -13 % ¥ 13.2 billion -62 % / -65% -7 % / -12 % -5 % / -10 % Adj
Slide 6: Business Topics
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 02 Business Topics
Slide 7: Completing Our Quality Transformation with Urgency
Completing Our Quality Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Transformation with Urgency Our highest priority is providing our customers with safe and effective solutions for patient care. Present Future Elevate Olympus continues to be committed to
Slide 8: Turning to Innovation and Key Products Expected to Drive Sales Growth
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Turning to Innovation and Key Products Expected to Drive Sales Growth First-time and major-market launches, with contributions expected from Q2 FY2026. PJ Elevate has improved the speed of regulatory clearan
Slide 9: The Power of Advanced Endoscopy, Reaching More Patients
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix The Power of Advanced Endoscopy, Reaching More Patients Growing the ecosystem for endoscopy-based care with innovative technologies. Better Care and Access for More Advanced Procedures at Scale Patients Expandin
Slide 10: Co-founding Swan EndoSurgical to advance endoluminal robotics
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Co-founding Swan EndoSurgical to advance endoluminal robotics 2B Growing market for Market size by 2040 for Our Vision for the future Over endoluminal robotic endoluminal robotic procedures USD surgery in the U.
Slide 11: Building a Stronger, Faster, and More Focused Olympus
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Building a Stronger, Faster, and More Focused Olympus 1 Bringing sharper business discipline and faster decision-making through a simplified divisional structure. 2 Raising the bar on leadership accountability w
Slide 12: 1Q of Fiscal Year 2026 Consolidated Financial Results
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 03 1Q of Fiscal Year 2026 Consolidated Financial Results
Slide 13: 1Q of Fiscal Year 2026 Consolidated Financial Results
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Consolidated Financial Results 1 Revenue: Decreased in major regions, except APAC. In particular, North America’s 1Q FY2026 was soft vs. a strong 1Q FY2025, due to the previous fiscal year
Slide 14: 1Q of Gastrointestinal Solutions Division
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Gastrointestinal Solutions Division (Billions of yen) FY2025 1Q FY2026 1Q 45%1 Revenue 159.6 139.0 40%1 Operating profit 35.1 18.1 Revenue ¥139.0 Other income and expenses Adjusted operati
Slide 15: 1Q of Surgical & Interventional Solutions Division
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Surgical & Interventional Solutions Division 20%1 (Billions of yen) FY2025 1Q FY2026 1Q 40%1 Revenue 75.1 67.4 Revenue Operating profit -2.1 -1.9 ¥67.4 Other income and expenses Adjusted o
Slide 16: Consolidated Statement of Financial Position
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Consolidated Statement of Financial Position 1 Assets: Increased due mainly to an increase in inventories, while cash and cash equivalents decreased. 2 Liabilities: Increased due mainly to fundraising through co
Slide 17: Consolidated Cash Flows
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Consolidated Cash Flows 1 FCF: Negative ¥32.7 billion due mainly to a decrease in profit before tax and payment of corporate income tax. Adjusted FCF1 was negative ¥17.5 billion. 2 Financing CF: Positive ¥22.5 b
Slide 18: Fiscal Year Consolidated Forecasts
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 04 Fiscal Year 2026 Consolidated Forecasts
Slide 19: Consolidated Forecasts (vs. Previous Forecasts)
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Fiscal Year 2026 Consolidated Forecasts (vs. Previous Forecasts) Revised full-year forecasts due mainly to U.S. tariffs and FDA Import Alerts. The management team is committed to tightly managing SG&A expenses t
Slide 20: Forecast Factors that Affected Adjusted Consolidated Operating Profit
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Fiscal Year 2026 Forecast Factors that Affected Adjusted Consolidated Operating Profit (vs. Previous Forecasts) (Billions of yen) Change in sales -10.2 Impact on revenue Impact of foreign (Approx. -¥15 billion
Slide 21: Consolidated Forecasts (vs. Previous Fiscal Year)
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Fiscal Year 2026 Consolidated Forecasts (vs. Previous Fiscal Year) 1 Revenue: ¥998.0 billion on a par with previous fiscal year. Expecting steady growth of 3% after FX adjustment. 2 Adjusted operating profit: ¥1
Slide 22: OLYMPUS
OLYMPUS
Slide 23: Appendix
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 05 Appendix
Slide 24: 1Q of Factors that Affected Consolidated Adjusted Operating Profit
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Factors that Affected Consolidated Adjusted Operating Profit 1Q (Apr. to Jun.) (Billions of yen) Change in SG&A expenses -8.6 R&D expenses related Impact of to next-generation GI foreign
Slide 25: 1Q of Results by Segment
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Results by Segment After FX FY2026 Latest (Billions of yen) FY2025 1Q FY2026 1Q YoY adjustment Forecasts Revenue 159.6 139.0 -13% -8% 679.5 GIS Operating profit 35.1 18.1 -48% -45% 149.5 R
Slide 26: Key Product Catalysts: Gastrointestinal Solutions Division
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Key Product Catalysts: Gastrointestinal Solutions Division (As of August 8, 2025) GIS Key Strategy for FY2026 GI Endoscopy Start Phase 2 of EVIS X1 U.S. launch with differentiated “Extended Depth of Field” EDO
Slide 27: Key Product Catalysts: Surgical & Interventional Solutions Division
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Key Product Catalysts: Surgical & Interventional Solutions Division (As of August 8, 2025) SIS Key Strategy for FY2026 Urology Expand leadership in BPH through iTind market development while increasing penetra
Slide 28: 1Q of Other Income and Expenses
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix 1Q of Fiscal Year 2026 Other Income and Expenses (Billions of yen) FY2025 1Q FY2026 1Q Change Other income 0.6 7.0 +6.4 Consideration based on agreement regarding license Major items usage rights, etc. with Ev
Slide 29: Capital Allocation
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Capital Allocation Policy FY2026 Prioritize allocation to business investment Active investment in three focus areas Stable and gradual dividend increase Plan to increase annual dividend by ¥10/share YoY to ¥30/
Slide 30: Forecast Factors that Affect Adjusted Consolidated Operating Profit
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Fiscal Year 2026 Forecast Factors that Affect Adjusted Consolidated Operating Profit (vs. Previous Fiscal Year) Change in Change in cost sales +18.4 of sales GIS: Sales expansion of -19.5 Change in SG&A new pr
Slide 31: Forecasts by Business Segment
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Fiscal Year 2026 Forecasts by Business Segment 1 GIS: After FX adjustment, while revenue expected to increase, driven by new products in EVIS X1 in North America, profit expected to decrease due to an increase i
Slide 32: Expenditures: 1Q of Actuals and Forecasts
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Expenditures: 1Q of Fiscal Year 2026 Actuals and Fiscal Year 2026 Forecasts 1Q results and Forecasts (Billions of yen) FY2025 1Q FY2026 1Q FY2026 (Forecasts) (Billions of yen) FY2025 FY2026 R&D expenditures1 (a)
Slide 33: Foreign Exchange and Sensitivity
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Foreign Exchange and Sensitivity As a general rule, we use average value for latest month as exchange rates for full-year forecasts. Foreign exchange rate (Yen) FY2025 1Q FY2026 1Q FY2026 Forecasts Yen/U.S.dolla
Slide 34: Acronyms
Table of Executive Business Financial contents Summary Topics Results Forecasts Appendix Acronyms Acronyms Term APAC Asia Pacific BPH Benign Prostatic Hyperplasia EBUS-TBNA Endobronchial Ultrasound-guided Transbronchial Fine Needle Aspiration ERCP Endoscopic Retrograde Cholangio Pancreatography ESD